DSG Capital Advisors LLC Purchases 830 Shares of McKesson Corporation $MCK

DSG Capital Advisors LLC raised its position in McKesson Corporation (NYSE:MCK) by 52.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,400 shares of the company’s stock after purchasing an additional 830 shares during the quarter. DSG Capital Advisors LLC’s holdings in McKesson were worth $2,026,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. State Street Corp raised its position in McKesson by 0.9% in the third quarter. State Street Corp now owns 5,750,519 shares of the company’s stock valued at $4,447,110,000 after purchasing an additional 51,510 shares during the last quarter. Franklin Resources Inc. raised its position in McKesson by 3.5% in the third quarter. Franklin Resources Inc. now owns 2,681,321 shares of the company’s stock valued at $2,071,428,000 after purchasing an additional 90,948 shares during the last quarter. Alliancebernstein L.P. raised its position in McKesson by 5.6% in the third quarter. Alliancebernstein L.P. now owns 2,394,699 shares of the company’s stock valued at $1,850,001,000 after purchasing an additional 126,684 shares during the last quarter. Northern Trust Corp raised its position in McKesson by 0.4% in the third quarter. Northern Trust Corp now owns 1,532,856 shares of the company’s stock valued at $1,184,193,000 after purchasing an additional 6,613 shares during the last quarter. Finally, Boston Partners raised its position in McKesson by 6.7% in the third quarter. Boston Partners now owns 1,330,953 shares of the company’s stock valued at $1,027,569,000 after purchasing an additional 83,357 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Leann B. Smith sold 190 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the sale, the executive vice president owned 2,989 shares of the company’s stock, valued at $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michele Lau sold 2,725 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total value of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares of the company’s stock, valued at $3,214,530. This represents a 45.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,592 shares of company stock worth $3,518,555. Company insiders own 0.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MCK shares. Weiss Ratings downgraded McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Leerink Partners restated an “outperform” rating and set a $1,085.00 price objective on shares of McKesson in a research report on Thursday, March 5th. Raymond James Financial set a $970.00 price objective on McKesson in a research report on Thursday, March 5th. Mizuho raised their price objective on McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Finally, Barclays raised their price objective on McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $970.93.

McKesson Price Performance

Shares of MCK opened at $857.67 on Tuesday. McKesson Corporation has a 1 year low of $637.00 and a 1 year high of $999.00. The company has a market capitalization of $105.06 billion, a price-to-earnings ratio of 24.67, a price-to-earnings-growth ratio of 1.25 and a beta of 0.42. The business has a 50-day moving average of $912.12 and a 200-day moving average of $856.26.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same period last year, the company earned $8.03 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, sell-side analysts anticipate that McKesson Corporation will post 39.02 EPS for the current year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 1st. Investors of record on Monday, March 2nd were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.